Kidney Cancer Vaccine Disappoints

Article

The tumor-derived vaccine vitespen (Oncophage) does not prevent renal-cell carcinoma recurrence or improve survival despite promising early results.

The tumor-derived vaccine vitespen (Oncophage) does not prevent renal-cell carcinoma recurrence or improve survival despite promising early results.

Related Videos
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
David Brown, MD | Image Credit: Retina Consultants of Texas
Heart Failure stock imagery. | Credit: Fotolia
The HCPLive 5 | Image Credit: HCPLive
James Palmer, MD | Credit: Penn Medicine
© 2024 MJH Life Sciences

All rights reserved.